Search for: "Grant v. Bristol-Myers Squibb"
Results 101 - 120
of 140
Sorted by Relevance
|
Sort by Date
11 Mar 2019, 10:15 am
Bristol-Myers Squibb Co., 919 F.3d 699 (2d Cir. 2019) followed suit and unanimously affirmed snap removal as a procedural vehicle to remove to federal court. [read post]
10 Jul 2008, 5:31 pm
Bristol-Myers Squibb Co., 121 F. [read post]
15 Oct 2008, 3:02 pm
The Supreme Court wil shortly hear these arguments in the context of a drug case and FDA preamble that attempts to grant immunity, when Wyeth v. [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) – US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is… [read post]
10 Sep 2012, 7:28 pm
Mich. 1996); Bristol-Myers Squibb Co. v. [read post]
5 Oct 2020, 9:01 pm
Should the Court now adopt a restrictive interpretation of the phrase “arises out of or relate to,” it would limit specific personal jurisdiction in a way that would benefit corporate manufacturers at the expense of consumers.Justice Sonia Sotomayor articulated this concern in her dissent in Bristol-Myers Squibb v. [read post]
3 Mar 2009, 5:55 am
What caught my eye, however, was the court's description of the order appealed from, viz, one granting "those parts of the motion of defendants seeking dismissal of the negligence and slander causes of action and the punitive damages claim. [read post]
4 Oct 2023, 10:00 pm
The Plaintiffs in the remaining five lawsuits (Merck, Bristol Myers Squibb, PhRMA and other trade associations, Janssen pharmaceutical, and Boehringer Ingelheim) might similarly amend their complaints to note that their drugs were in fact selected, and that they were compelled to sign contracts with the CMS. [read post]
6 May 2016, 12:30 pm
Bean v. [read post]
2 Nov 2009, 1:24 pm
At the Wall Street Journal, Dow Jones Newswire’s Kristina Peterson addresses the Court’s denial of cert. in a drug-patent dispute between generic drug manufacturer Apotex Corp. and patent-holders Sanofi-Aventis and Bristol-Myers Squibb, while the Associated Press has coverage of the Court’s decision not to hear an appeal to stop the release of documents relating to sexual abuse lawsuits against Roman Catholic priests in… [read post]
16 Feb 2021, 12:19 pm
For example, the Georgia Court of Appeals found that a tax return preparation firm made reasonable efforts to maintain the secrecy of its customers’ list because it: (i) did not publish the list; (ii) established companywide policies to protect the information from disclosure to third parties; (iii) counseled its employees regarding the policies; (iv) limited access to its customer database to certain employees and the information was password protected; and (v) employees permitted… [read post]
5 Nov 2007, 12:58 pm
Bristol-Myers Squibb, 97 F. [read post]
5 Jun 2013, 5:29 am
Bristol-Myers Squibb, 97 F. [read post]
6 Jun 2013, 5:00 am
Bristol-Myers Squibb Co., No. 12 Civ. 2238 (JPO), slip op. [read post]
20 Mar 2023, 7:52 am
Shikada v. [read post]
11 Jan 2017, 7:19 am
Utah rule, to satisfy the three-year time limitation in Section 13 of the Securities Act with respect to the claims of putative class members (Question granted in Public Employees’ Retirement System of Mississippi v. [read post]
18 Jul 2014, 11:55 am
Jan. 11, 2013), reconsideration granted, No. 1101397 (Ala. [read post]
21 Jun 2012, 7:40 am
Bristol-Myers Squibb Co., 2009 WL 5216982, at *5-6 (D.N.J. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
25 Apr 2015, 11:03 am
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
